No Data
No Data
Sichuan Shuangma: 2024 Annual Results Forecast
Express News | Sichuan Hexie Shuangma: Expected net income for 2024 to decrease by 71.59% - 61.44% year-on-year.
Sichuan Hexie Shuangma (000935): Pharmaceutical Technology + PE dual core drives high performance growth.
The investment logic is that the company has transitioned from a single Cement business to a primary focus on private equity business, achieving a leap in Net income and ROE. Under the industrial + industrial capital model, it is expected to develop a dual core business of Biotechnology + Fund management in the future. Sichuan Hexie Shuangma becomes.
The competition is fierce! Musk once said that "Tirzepatide", which is more effective than semaglutide, will be launched in China. Who will dominate the weight loss drug market in 2025?
① Today, Eli Lilly and Co announced the official launch of tirzepatide in China, covering both type 2 diabetes and weight loss, and it is already available on some online platforms; ② Musk has claimed that tirzepatide is better than semaglutide, while the market is more focused on the pricing of tirzepatide and whether it will be included in medical insurance; ③ The competition in the GLP-1 sector will become even more intense in 2025, with Jiangsu Hengrui Pharmaceuticals, INNOVENT BIO, and Gan & Lee Pharmaceuticals receiving widespread attention.
Express News | Sichuan Hexie Shuangma: Hubei Jianxiang has obtained export certification documents for the European Union.
Express News | Sichuan Hexie Shuangma: Subsidiary Hubei Jianxiang passed the on-site inspection by the USA FDA.